International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers

Core Insights - Bionano Laboratories has announced expert recommendations for integrating Optical Genome Mapping (OGM) as a standard-of-care cytogenetic assay in various clinical settings, as published in the American Journal of Hematology [1][2] Group 1: Expert Recommendations - OGM is recommended as a first-line test for Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN), B-cell Acute Lymphoblastic Leukemia (B-ALL), T-cell Acute Lymphoblastic Leukemia (T-ALL), pediatric leukemias, and unexplained eosinophilia [3] - OGM is suggested as an alternative to traditional methods like karyotyping, FISH, and CMA for Chronic Lymphocytic Leukemia (CLL), Plasma Cell Neoplasms/Multiple Myeloma, aplastic anemia, bone marrow failure syndromes, and germline predisposition syndromes [4] Group 2: Advantages of OGM - OGM provides higher diagnostic clarity and simplifies laboratory workflows, making it more cost-effective with faster turnaround times [5] - OGM allows for the identification of cryptic gene fusions for which targeted therapies may be available, improving risk stratification and guiding targeted therapy [7] - OGM can resolve complex or ambiguous chromosomal abnormalities and is effective for low-frequency or rare hematologic malignancies [7] Group 3: Company Overview - Bionano Laboratories offers CLIA-certified laboratory developed tests (LDTs) based on OGM, aiming to transform genome analysis in clinical diagnostics [1][9] - The company provides a comprehensive testing portfolio and support options for applications across basic, translational, and clinical research [8][9]